On August 6, 2026, Tiziana Life Sciences Ltd announced that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on NASDAQ at $1.00 per share. This transaction increased his total holdings to 4,793,684 common shares. The company is a clinical-stage biopharmaceutical firm developing immunomodulation therapies, specifically the intranasal anti-CD3 monoclonal antibody foralumab.
